Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Prevention of Respiratory Viral Infection: Vaccine, Antiviral and Immune-Modulator"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 August 2017) | Viewed by 25208
Special Issue Editor
2. BIOTARGEN EA 7450, Normandie Université, 14280 Saint Contest, France
Interests: equine infectious diseases; immunology; vaccination; equine influenza
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pathogens: Research on Herpesviruses of Equids
Special Issue in Viruses: Equine Influenza 2023
Special Issue Information
Respiratory viral infections are a major welfare and economic concern to both human and animal species. Prevention is often essential and requires multiple different strategies to successfully reduce the risk of infections, their frequency, and dissemination.
To date, vaccination is one of the most effective methods of prevention against a broad range of respiratory pathogens. It is particularly efficacious when combined to active pathogen/disease surveillance, host population management to maximise herd immunity, and quarantine when applicable. A lot of effort has been made in the last decades to improve vaccines against respiratory virus, including the design of new vaccine technologies (e.g., modified live attenuated and recombinant vector based vaccines) to broaden the immune response generated (e.g., mucosal and/or cell-mediated immunity). Incorporation of DIVA markers (Differentiating Infected from Vaccinated Animals) proves to be increasingly important for pathogen/disease surveillance. However, while vaccination against specific pathogens, such as influenza viruses, is well established in numerous species, efficient vaccines against others remain elusive (e.g., herpesvirus). Beyond the vaccine itself, numerous elements need to be taken into account in order to maximise prevention (e.g., the schedule of administration, population coverage and host specificities). In some cases, when vaccine performance is limited or overcome, the use of antivirals or immune-modulators to reduce the impact and consequences of infection is envisaged.
The main focus of this Special Issue of Vaccines is to discuss these important aspects of the prevention against respiratory viruses and to present recent results from vaccine studies and trials.
Dr. Romain Paillot
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- infectious diseases
- respiratory infection
- influenza virus
- herpes virus
- animal models